MedPath

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Conditions
Schizophrenia
MedDRA version: 17.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disorders
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Registration Number
EUCTR2012-002785-12-DE
Lead Sponsor
H. Lundbeck A/S
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
286
Inclusion Criteria

1. The patient has schizophrenia, diagnosed according to DSM-IV-TR®.
2. The patient has a CGI-S score from mildly ill to markedly ill at the Screening and Baseline Visit(s).
3. The patient is in need of a change in the current antipsychotic treatment and in the judgement of the investigator the patient would benefit from an extended treatment with a once-monthly formulation.
4. The patient agrees to protocol-defined use of effective contraception.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 286
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

1. The patient has any current psychiatric disorder or Axis I disorder (DSMIV ® criteria) other than schizophrenia established as the primary diagnosis.
2. The patient is experiencing acute exacerbation of psychotic symptoms at the Screening Visit or between the Screening and Baseline Visits.
3. The patient in the investigator's judgment has shown significant intolerance and/or lack of efficacy to oral aripiprazole, paliperidone or risperidone.
4. The patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).
5. The patient has a history of neuroleptic malignant syndrome.
The patient has any relevant medical history or current presence of systemic disease
6. The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath